This translation is automatically provided by Google; please refer to the original English version for appropriate wording.

Country-specific results

The costs and benefits of introducing typhoid conjugate vaccines (TCVs) vary for each country depending on a variety of country-specific inputs. Dive into the specific cost-effectiveness inputs and outputs for each of the 73 Gavi-eligible countries highlighted below-and make adjustments to see how the results may change with varying circumstances.

Select a country

Begin by searching for country name field below, or choose from the map.

* NOTE: For conjecture only; model input adjustments outside of published assumptions are not supported by evidence and any adjusted results- have not been corroborated by the researchers or TyVAC.

NOTE: The background, methods, results and discussion of this analysis are presented in detail in Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study. The content presented here should be considered together with this manuscript. Any changes to inputs away from those considered in the manuscript cannot be cited or referenced as such.

Top